Strategic Planning & Communication Flashcards

A regulatory affairs professional is preparing a briefing document for a Type B FDA meeting. Which element is MOST critical to include to make the meeting productive?

Answer: Specific questions formatted to elicit yes/no agency commitments

FDA expects specific, clearly worded questions in briefing documents so the agency can provide focused, actionable responses during the meeting.

Which ICH guideline provides a framework for assessing genotoxic impurities in pharmaceutical products, directly influencing regulatory submission strategy?

Answer: ICH M7

ICH M7 provides guidance on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals, setting acceptable intake thresholds.

A company must decide whether to pursue Breakthrough Therapy designation for a new oncology drug. Which criterion is MOST relevant to this designation?

Answer: Preliminary clinical evidence shows substantial improvement over existing therapies for a serious condition

Breakthrough Therapy designation requires preliminary clinical evidence showing substantial improvement over available therapies on a clinically significant endpoint for a serious condition.

In strategic regulatory planning, what does 'benefit-risk communication' primarily involve?

Answer: Transparently conveying the balance between a product's therapeutic benefits and its known risks to regulators and patients

Benefit-risk communication involves clearly presenting and contextualizing both the therapeutic benefits and the safety risks of a product to regulators, prescribers, and patients.

A company submitting an NDA receives a Complete Response Letter (CRL) from FDA. What is the MOST appropriate immediate strategic response?

Answer: Conduct a thorough analysis of the CRL deficiencies and request a Type A meeting to discuss the path forward

Analyzing the CRL deficiencies thoroughly and requesting a Type A meeting allows the sponsor to clarify FDA's concerns and develop a targeted remediation plan.

Which of the following BEST describes the purpose of a regulatory gap analysis?

Answer: Comparing current data packages against agency requirements to identify missing or insufficient evidence

A regulatory gap analysis systematically compares the existing data package against regulatory requirements to identify deficiencies that must be addressed before submission.

Under the EU MDR (Regulation 2017/745), which body is responsible for reviewing and certifying medical devices before they can be CE marked?

Answer: A designated Notified Body

Under EU MDR, Notified Bodies are accredited third-party organizations designated to perform conformity assessments and issue CE certificates for medical devices.